Skip to main content
. 2018 Apr 3;9(25):17523–17532. doi: 10.18632/oncotarget.24778

Table 3. Frequencies of KIR-HLA combinations among individuals with symptomatic acute encephalitis and healthy subjects.

KIR and HLA
combinations
Subjects with acute encephalitis
(n: 30)
Subjects without acute encephalitis
(n: 36)
p
2DL 2-HLA-C1 (n/%) 5 (16.6) 15 (50) 0.028
2DL 3-HLA-C1 (n/%) 4 (13.3) 12 (33.3) 0.059
2DS2-HLA-C1 (n/%) 4 (13.3) 11 (30.5) 0.096
2DS2-HLA-C2 (n/%) 1 (3.3) 2 (5.5) 0.66
2DL2- HLA-C2 (n/%) 4 (13.3) 4 (11.1) 0.78
2DS1-HLA-C2 (n/%) 5 (16.6) 4 (11.1) 0.51
2DL1-HLA-C1 (n/%) 6 (20) 3 (8.3) 0.16
2DL1-HLA-C2 (n/%) 3 (10) 4 (11.1) 0.88
3DL1-HLA-Bw4T (n/%) 9 (30) 4 (11.1) 0.055
3DS1-HLA-Bw4T (n/%) 4 (13.3) 6 (16.6) 0.70
3DS1-HLA-A-BW4 (n/%) 4 (13.3) 6 (16.6) 0.707
3DS1-HLA-B-BW4T (n/%) 4 (13.3) 6 (16.6) 0.707
3DS1-HLA-B-BW4I (n/%) 3 (10) 4 (11.1) 1.0
3DL1-HLA-A-BW4 (n/%) 4 (13.3) 3 (8.3) 0.693
3 DL1-HLA-B-BW4T (n/%) 9 (30) 4 (11.1) 0.055
3DL1-HLA-B-BW4I (n/%) 4 (13.3) 3 (8.3) 0.693

KIR: Killer-cell immunoglobulin-like receptors; HLA: human leukocyte antigen.